Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature

Alternative Medicine Review

Volumn 6, Issue 3, 2001, Pages 248-271

  Patrick, L ^a   Uzick, M ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID A PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; CHOLESTEROL; FIBRINOGEN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; OLIVE OIL; OLIVE OIL POLYPHENOL; PRAVASTATIN; RED YEAST RICE; SEX HORMONE; SIMVASTATIN; UNCLASSIFIED DRUG;

ACUTE PHASE RESPONSE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; HOMEOSTASIS; HORMONE SUBSTITUTION; HUMAN; INFECTION; INFLAMMATION; PROTEIN ANALYSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; THEORY;

ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; BIOLOGICAL PRODUCTS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; FATTY ACIDS; FEMALE; FLAVONOIDS; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MALE; NAPHTHALENES; PHENOLS; PHOSPHORUS; PLANT OILS; POLYMERS; PROTEINS; STARCH; VITAMIN E;

EID: 0034962510     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. Shattuck lecture - Cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities
2. Detailed diagnoses and procedures for patients discharged from short-stay hospitals
3. Mortality from tobacco in developed countries: Indirect estimation from national vital statistics
4. Homocysteine metabolism: Nutritional modulation and impact on health and disease
5. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors
6. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening
7. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study
8. Atherosclerosis- An inflammatory disease
9. C-reactive protein, inflammation, and coronary risk
10. Low density lipoprotein oxidation and its pathobiological significance
11. Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates
12. Enhanced macrophage uptake of low density lipoprotein after self-aggregation
13. Glycation and oxidation: A role in the pathogenesis of atherosclerosis
14. Scavenger receptors in innate immunity
15. Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis
16. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults
17. The pathogenesis of atherosclerosis: A perspective for the 1990s
18. Association of coronary plaque rupture and atherosclerotic inflammation
19. Plaque fissuring - The cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina
20. Lipid lowering and plaque regression. New insights into prevention of plaque clinical events in coronary disease
21. A macro and micro view of coronary vascular insult in ischemic heart disease
22. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
23. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease
24. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction
25. Interleukin-6 and the acute phase response
26. C-reactive protein and the acute phase response
27. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas
28. Immunohistochemical localization of C-reactive protein-binding sites in human atherosclerotic aortic lesions by a modified streptavidinbiotin-staining method
29. The acute phase response and C-reactive protein
30. Elevated levels of interleukin-6 in unstable angina
31. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increasing risk of in-hospital coronary events
32. Human atherosclerotic abdominal aortic aneurysms produce interleukin (IL)-6 and interferon-gamma but not IL-2 and IL-4: The possible role for IL-6 and interferon-gamma in vascular inflammation
33. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction
34. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men
35. A prospective study of fibrinogen and risk of myocardial infarction in the physicians' health study
36. Elevation of C-reactive protein in "active" coronary artery disease
37. Serum C-reactive protein and fibrinogen concentrations and self-reported angina pectoris and myocardial infarction: Findings from National Health and Nutrition Examination Survey III
38. Long-term effects of pravastatin on plasma concentration of C-reactive protein
39. Plasma C-reactive protein, systolic hypertension and risk of ischemic stroke and TIA: The Framingham study
40. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke
41. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease
42. High levels of plasma C-reactive protein and future risk of age-related cataract
43. C-reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study
44. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the cardiovascular health study and the rural health promotion project
45. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study
46. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992
47. Infections, inflammation, and the risk of coronary heart disease
48. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
49. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
50. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
51. Hormone replacement therapy and increased plasma concentration of C-reactive protein
52. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) study
53. Infection as a risk factor for infarction and atherosclerosis
54. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki heart study
55. Prevalence of chlamydia antibodies in patients with coronary heart disease
56. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction
57. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: The West Birmingham stroke project
58. Emerging relations between infectious diseases and coronary artery disease and atherosclerosis
59. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery
60. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries
61. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model
62. Persistent infection and vascular disease: A systematic review
63. Chlamydia pneumoniae and atherosclerosis
64. Antibiotics and risk of subsequent first-time acute myocardial infarction
65. Past use of erythromycin, tetracycline, or doxycycline is not associated with risk of first myocardial infarction
66. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction
67. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: Primary clinical results of the ACADEMIC study
68. Anti-inflammatory activity of macrolide antibiotics
69. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study
70. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering
71. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
72. Lipid lowering and beyond: Results from the CARE study on lipoproteins and inflammation. Cholesterol and recurrent events
73. Cost-effectiveness of primary care
74. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
75. Statins do more than just lower cholesterol
76. Statins for stroke: The second story?
77. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits
78. Associations between change in C-reactive protein and serum lipids during statin treatment
79. Adverse effects list and discussion for pravastatin, simvastatin, atorvastatin, cerivastatin, lovastatin
80. Toxic liver damage caused by HMG-CoA reductase inhibitor
81. Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: A report of ten cases
82. Distinct drug-interaction profiles for statins
83. Comparative tolerability of HMG-coA-reductase inhibitors
84. Statins and peripheral neuropathy
85. Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors
86. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro
87. Statins as a newly recognized type of immunomodulator
88. Monascus purpureus-fermented rice (red yeast rice): A natural food product that lowers blood cholesterol in animal models of hypercholesterolemia
89. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement
90. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up
91. Multicenter clinical trial of the serum lipid-lowering effects of a Monascus purpureus (red yeast) rice preparation from traditional Chinese medicine
92. Role of vitamin E in preventing the oxidation of low-density lipoprotein
93. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation?
94. Oxidized low-density lipoprotein is cytotoxic to human monocyte-macrophages: Protection with lipophilic antioxidants
95. Effect of dietary antioxidant combinations in humans. Protection of LDL by vitamin E but not by beta-carotene
96. Antioxidants and atherosclerotic heart disease
97. The effects of alpha-tocopherol on critical cells in atherogenesis
98. Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells
99. Alpha-Tocopherol enrichment of monocytes decreases agonist-induced adhesion to human endothelial cells
100. Inhibition of smooth muscle cell proliferation and protein kinase C activity by tocopherols and tocotrienols
101. Alpha-tocopherol, an effective inhibitor of platelet adhesion
102. The effects of alpha tocopherol supplementation on monocyte function. Decreased lipid oxidation, interleukin 1 beta secretion, and monocyte adhesion to endothelium
103. Vitamin E supplementation and cardiovascular events in high-risk patients
104. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)
105. Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks
106. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-prevenzione trial
107. GISSI-prevenzione trial
108. Vitamin E and heart disease: Basic science to clinical intervention trials
109. Dietary vitamin E requirement for optimum immune responses in the rat
110. Effect of oral supplementation with D-alpha-tocopherol on the vitamin E content of human low density lipoproteins and resistance to oxidation
111. Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients
112. Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes
113. Is type II diabetes mellitus a disease of the innate immune system?
114. NIDDM as a disease of the innate immune system: Association of acute-phase reactants and interleukin-6 with metabolic syndrome X
115. Tolerance and safety of vitamin E: A toxicological position report
116. Antioxidant protection of low density lipoprotein and its role in the prevention of atherosclerotic vascular disease
117. Preservation of endogenous antioxidants in low density lipoprotein by ascorbate but not probucol during oxidative modification
118. Aortic ascorbic acid, trace elements, and superoxide dismutase activity in human aneurysmal and occlusive disease
119. Plasma levels of antioxidant vitamins in relation to ischemic heart disease and cancer
120. Effect of a mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease. Insights into the cardioprotective effect of certain nutriments
121. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: Final report of the Lyon diet heart study
122. Dietary prevention of coronary heart disease: The Lyon diet heart study
123. Olive oil and reduced need for antihypertensive medications
124. Plasma lipids, erythrocyte membrane lipids and blood pressure of hypertensive women after ingestion of dietary oleic acid from two different sources
125. Effects induced by olive oil-rich diet on erythrocytes membrane lipids and sodium-potassium transports in postmenopausal hypertensive women
126. Dietary olive oil reduces low-density lipoprotein uptake by macrophages and decreases the susceptibility of the lipoprotein to undergo lipid peroxidation
127. Dietary non-tocopherol antioxidants present in extra virgin olive oil increase the resistance of low density lipoproteins to oxidation in rabbits
128. Dietary flavonoids, antioxidant vitamins, and incidence of stroke: The Zutphen study
129. Effect of virgin olive oil phenolic compounds on in vitro oxidation of human low density lipoproteins
130. Protective effect of oleuropein, an olive oil biophenol, on low density lipoprotein oxidizability in rabbits
131. Polyphenolic flavonoids inhibit macrophage-mediated oxidation of LDL and attenuate atherogenesis
132. Probucol inhibits oxidative modification of low density lipoprotein
133. Measurement of reactive oxygen species by chemiluminescence in diet-induced atherosclerosis: Protective roles of vitamin E and probucol on different radical species